OSLO, 31 August 2026: As part of the long-term incentive programme of EXACT
Therapeutics AS ("The Company"), a total of 1,300,000 share options have been
granted to the employees of the Company, of which 780,000 share options have
been granted to primary insiders.
Each option, when exercised, gives the right to acquire one share in the
Company. The strike price for the options is NOK 0.73 , equal to the
volume-weighted average price of the Company's share over the last 10 days of
trading in the share and will vest over a period of up to three years.
The required form of notification and public disclosure by primary insiders
related to the grant is attached to this announcement.
This information is subject to the disclosure requirements in Regulation EU
596/2014 (MAR) article 19 number 3 and section 5-12 of the Norwegian Securities
Trading Act.
For more information, please contact:
Per Walday, CEO
EXACT Therapeutics
per.walday@exact-tx.com
About EXACT Therapeutics:
EXACT Therapeutics is a clinical-stage precision medicine company utilizing the
power of ultrasound to activate the proprietary drug PS101 and enhance the
clinical benefit of oncology therapies. PS101 has a unique mode of action and
may be combined with a wide range of therapeutic agents within oncology and
across a multitude of other indications, including brain diseases. EXACT
Therapeutics' shares are currently traded on Euronext Growth Oslo (EXTX). An
application for delisting of the shares has been approved by Oslo Stock
Exchange, and last day of trading is 9 October, 2026. Further information may
be found here: www.exact-tx.com
formation may\
be found here: www.exact-tx.com\